Alseres CEO notes molecular-imaging candidate is in Phase III studies

06/12/2008 | PharmaLive.com

Alseres Pharmaceuticals' lead molecular-imaging candidate, Altropane, is in two-part Phase III clinical trials to test its diagnostic efficacy in Parkinson's disease patients with tremor, according to the company chairman and CEO's annual letter to stockholders.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC